Long-term follow-up for breast cancer patients from GBG trials
Registry for Long-term Follow-up of Safety and Efficacy Parameters of GBG Study Participants
This study is looking to see how well different treatments work for early breast cancer patients over the long term and how they affect things like survival, side effects, and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | GBG Forschungs GmbH Academic / other |
| Locations | 3 sites (Innsbruck and 2 other locations) |
| Trial ID | NCT05739591 on ClinicalTrials.gov |
What this trial studies
The ETERNITY study is an international, multicenter, observational initiative designed to collect long-term safety and efficacy data from patients who participated in GBG trials for early breast cancer. This study will gather information on survival rates, late adverse events, and factors affecting quality of life, such as pregnancy and fertility. Patients will be registered after providing informed consent, and their follow-up data will be documented annually. The study aims to correlate long-term outcomes with the specific therapies received during the initial trials.
Who should consider this trial
Good fit: Ideal candidates are individuals who have previously participated in a GBG clinical trial for early breast cancer.
Not a fit: Patients who have participated in non-GBG clinical trials or those with advanced or metastatic breast cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term effects of treatments for early breast cancer, improving patient care and management.
How similar studies have performed: Other studies focusing on long-term follow-up in cancer patients have shown success, indicating that this approach is both valuable and tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Participation and treatment in a GBG clinical trial for early breast cancer. * Prospective registration: Written informed consent according to local regulatory requirements prior to data and biomaterial collection. Exclusion criteria: * Participation and treatment in a non-GBG clinical trial for early breast cancer. * Patients with advanced or metastatic breast cancer who have participated and received treatment in a GBG clinical trial.
Where this trial is running
Innsbruck and 2 other locations
- MUI - Univ. Klinik f. Frauenheilkunde Innsbruck — Innsbruck, Austria (Recruiting)
- Ordensklinikum Linz GmbH - BHS — Linz, Austria (Recruiting)
- LKH Salzburg - PMU — Salzburg, Austria (Recruiting)
Study contacts
- Study coordinator: Thomas Ballhausen, Dr.
- Email: eternity@gbg.de
- Phone: 0049610274800
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.